|Name||PRICE||MARKET CAPITALIZATION||PRICE TO EARNINGS RATIO||DIVIDEND YIELD||SYMBOL||EXCHANGE||PRICE PERCENT DIFFERENCE||YEAR TO DATE PRICE PERCENT DIFFERENCE||5 YEAR CHART||1 YEAR CHART|
Ionis Pharmaceuticals Inc [IONS]
$68.56 0.68 (0.98%)
Market Cap 9.46 Billion
Ionis Pharmaceuticals Inc is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline treats a wide variety of diseases, with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis sold rights to its first product, Kynamro, to Kastle Therapeutics after lackluster commercial success, but with a partner, Biogen brought its second drug, Spinraza for spinal muscular atrophy, to market. ATTR amyloidosis drug Tegsedi (inotersen) was approved in 2018.
EPS 0.63 P/E Ratio 41.01
Previous Earnings Wed, Feb 27, 2019
Pay Date --
This list of trending stocks may change throughout the trading day.